Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 47: 292-300, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aguilera, R.
Right arrow Articles by Catlin, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aguilera, R.
Right arrow Articles by Catlin, D. H.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2001;47:292-300.)
© 2001 American Association for Clinical Chemistry, Inc.


Articles

Performance Characteristics of a Carbon Isotope Ratio Method for Detecting Doping with Testosterone Based on Urine Diols: Controls and Athletes with Elevated Testosterone/Epitestosterone Ratios

Rodrigo Aguilera1,a, Thomas E. Chapman1, Borislav Starcevic1, Caroline K. Hatton1 and Don H. Catlin1,2

1 UCLA Olympic Analytical Laboratory, Department of Molecular and Medical Pharmacology and
2 Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90025.

3 The word "elevated" is used to refer to a result that is above the administrative cutoff.
a Address correspondence to this author at: UCLA Olympic Analytical Laboratory, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, 2122 Granville Ave., Los Angeles, CA 90025-6106. Fax 310-206-9077; e-mail rodrigoa{at}ucla.edu.

Background: Carbon isotope ratio methods are used in doping control to determine whether urinary steroids are endogenous or pharmaceutical.

Methods: Gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) was used to determine the {delta}13C values for 5{beta}-androstane-3{alpha},17{beta}-diyl diacetate (5{beta}A), 5{alpha}-androstane-3{alpha},17{beta}-diyl diacetate (5{alpha}A), and 5{beta}-pregnane-3{alpha},20{alpha}-diyl diacetate (5{beta}P) in a control group of 73 healthy males and 6 athletes with testosterone/epitestosterone ratios (T/E) >6.

Results: The within-assay precision SDs for 5{beta}A, 5{alpha}A, and 5{beta}P were ± 0.27{per thousand}, ± 0.38{per thousand}, and ± 0.28{per thousand}, respectively. The between-assay precision SDs ranged from ± 0.40{per thousand} to ± 0.52{per thousand}. The system suitability and batch acceptance scheme is based on SDs. For the control group, the mean {delta}13C (SD) values were -25.69{per thousand} (± 0.92{per thousand}), -26.35{per thousand} (± 0.68{per thousand}), and -24.26{per thousand} (± 0.70{per thousand}), for 5{beta}A, 5{alpha}A, and 5{beta}P, respectively. 5{beta}P was greater than 5{beta}A and 5{alpha}A (P <0.01), and 5{beta}A was greater than 5{alpha}A (P <0.01). The means - 3 SD were -28.46{per thousand}, -28.39{per thousand}, and -26.37{per thousand} for 5{beta}A, 5{alpha}A, and 5{beta}P, respectively. The maximum difference between 5{beta}P and 5{beta}A was 3.2{per thousand}, and the maximum 5{beta}A/5{beta}P was 1.13. Three athletes with chronically elevated T/Es had {delta}13C values consistent with testosterone administration and three did not.

Conclusions: This GC-C-IRMS assay of urine diols has low within- and between-assay SDs; therefore, analysis of one urine sample suffices for doping control. The means, SDs, ±3 SDs, and ranges of {delta}13C values in a control group are established. In comparison, testosterone users have low 5{beta}A and 5{alpha}A, large differences between 5{beta}A or 5{alpha}A and 5{beta}P, and high 5{beta}A/5{beta}P and 5{alpha}A/5{beta}P ratios.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Endocrinol. Metab.Home page
J. J. Schulze, J. Lundmark, M. Garle, I. Skilving, L. Ekstrom, and A. Rane
Doping Test Results Dependent on Genotype of Uridine Diphospho-Glucuronosyl Transferase 2B17, the Major Enzyme for Testosterone Glucuronidation
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2500 - 2506.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
C Saudan, N Baume, N Robinson, L Avois, P Mangin, and M Saugy
Testosterone and doping control
Br. J. Sports Med., July 1, 2006; 40(suppl_1): i21 - i24.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Baume, L. Avois, C. Schweizer, C. Cardis, J. Dvorak, M. Cauderay, P. Mangin, and M. Saugy
[13C]Nandrolone Excretion in Trained Athletes: Interindividual Variability in Metabolism
Clin. Chem., February 1, 2004; 50(2): 355 - 364.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
R. Aguilera, C. K. Hatton, and D. H. Catlin
Detection of Epitestosterone Doping by Isotope Ratio Mass Spectrometry
Clin. Chem., April 1, 2002; 48(4): 629 - 636.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.